![\"\"](\"http:\/\/i.ytimg.com\/vi\/E3pyjKbQSHI\/0.jpg\")
<\/p>\n <\/p>\n
There are more and more biological drugs available on the market, ready to cure many different diseases: this is what emerges from the Report on biotechnologies in the pharmaceutical sector in Italy - 2014, produced by Farmindustria. There are 110 biotechnological medicines in Italy distributed in 12 therapeutic areas: 35 are for infectious diseases, 23 for oncological diseases, 21 for metabolic, hepatic and endocrine diseases. Of all these drugs, 21 have obtained orphan drug designation, while about a dozen are under study, some almost ready to enter the market. These are molecules for the treatment of: ovarian cancer; neurotrophic keratitis; retinitis pigmentosa; melanoma; Crohn's disease; multiple sclerosis; familial hypercholesterolaemia; hyperlipidemia; acute lymphoblastic leukemia; neuropathic cancer pain.<\/span><\/p>\n Thursday, June 19, 2014<\/span> \u2013 <\/i>Pharmacist<\/span><\/b>3<\/span><\/b>3<\/p>\n <\/span><\/p>\n <\/span><\/p>\n Biotech pharmaceuticals, +2.4% investments in research<\/p>\n <\/span><\/p>\n In Italy, the biotechnology sector is essentially identified with the drug sector: there are 176 companies, with investments in R&D of over 1 billion euros (+2.4% compared to 2013), a turnover that is close to 6 billion (+0.8%) and 4,658 employees in R&D (-2.7%). This is what emerges from the Report on biotechnologies in the pharmaceutical sector in Italy 2014, produced by Ernst&Young and Farmindustria, and presented in Rome. Of the 176 companies present in our country, 51 are drug companies.<\/span><\/span><\/p>\n <\/span><\/p>\n They represent the majority of the sector with a turnover of 5.465 billion euros (92% of the total), investments in R&D equal to 917 million euros (85% of the total), 3,498 workers employed in R&D (75% of the total); biotech (including, for example, companies dedicated exclusively to biotechnology).<\/span><\/span><\/p>\n <\/o:\n<\/p>","protected":false},"excerpt":{"rendered":" Sono sempre di più i farmaci biologici disponibili sul mercato, pronti a curare molte e diverse malattie: è quanto emerge dal Rapporto sulle biotecnologie del settore farmaceutico in Italia – 2014, realizzato da Farmindustria. I medicinali biotecnologici in Italia sono 110 distribuiti in 12 aree terapeutiche: 35 sono per le malattie infettive, 23 per …<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-18121","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/18121","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=18121"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/18121\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=18121"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=18121"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=18121"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}